Evidence map›Paper›PMID 28533242›Full record

ArticleAntimicrobial agents and chemotherapy2017

Coadministration of Liposomal Amphotericin B and Contrast Medium Does Not Increase Risk of Kidney Injury.

John C O'Horo, Douglas R Osmon, Omar M Abu Saleh, Jasmine R Marcelin, Kamel A Gharaibeh, Abdurrahman M Hamadah, Amelia K Barwise, Bryce M Kayhart, Jennifer S McDonald, Robert J McDonald and 1 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

John C O'HoroDivision of Infectious Diseases, Rochester, Minnesota, USA ohoro.john@mayo.edu.
Douglas R OsmonDivision of Infectious Diseases, Rochester, Minnesota, USA.
Omar M Abu SalehDivision of Infectious Diseases, Rochester, Minnesota, USA.
Jasmine R MarcelinDivision of Infectious Diseases, Rochester, Minnesota, USA.
Kamel A GharaibehDivision of Nephrology and Hypertension, Rochester, Minnesota, USA.
Abdurrahman M HamadahDivision of Nephrology and Hypertension, Rochester, Minnesota, USA.
Amelia K BarwiseDivision of Pulmonary and Critical Care Medicine, Rochester, Minnesota, USA.
Bryce M KayhartPharmacy Services, Rochester, Minnesota, USA.
Jennifer S McDonaldDepartment of Radiology, Mayo Clinic, Rochester, Minnesota, USA.
Robert J McDonaldDepartment of Radiology, Mayo Clinic, Rochester, Minnesota, USA.
Nelson LeungDivision of Nephrology and Hypertension, Rochester, Minnesota, USA.
University of Minnesota Rochester · USHypertension Institute · USMayo Clinic · US

Funding

Mayo Clinic Center for Translational Science ActivitiesUL1TR000135 · NCATS · MAYO CLINIC ROCHESTER · PI KHOSLA, SUNDEEP · 2012 to 2015
$41.2M
NCATS NIH HHS UL1 TR000135
6 · The paper itself

Abstract

Intravenous radiographic contrast medium and amphotericin B are commonly required in the care of patients with fungal infections. Both interventions have proposed nephrotoxicity through similar mechanisms. We systematically examined patients who received coadministration of liposomal amphotericin B (AmBisome; GE Healthcare) and intravenous contrast medium within a 24-h period and compared the results for those patients with the results for patients who underwent non-contrast medium studies. We found 114 cases and 85 controls during our study period. Overall, no increased risk of renal injury was seen with coadministration of these 2 agents. Adjustment for age, baseline kidney function, and other clinical factors through propensity score adjustment did not change this result. Our observations suggest that, when clinically indicated, coadministration of contrast medium and liposomal amphotericin B does not present excess risk compared with that from the administration of liposomal amphotericin B alone.

Indexed as

Acute Kidney InjuryAdultAmphotericin BAntifungal AgentsContrast MediaDrug Therapy, CombinationFemaleHumansKidneyMaleMetabolic Clearance RateMiddle AgedMycosesTomography, X-Ray ComputedAmphotericin BAntifungal AgentsContrast Medialiposomal amphotericin Bcomputed tomographyinvasive fungal infectionkidney injury

Identifiers

PMID28533242
PMCPMC5527596
OpenAlexW2619995610

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.